ZYMEWORKS INC. Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One
ZYMEWORKS INC. (ZYME) had Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One of $91.31 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $91.31M.
- 2026-03-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $120.41M.
- 2025-12-31: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $187.46M.
- 2025-09-30: Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One $186.93M.
| Period end | Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2026-06-30 | $91.31M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $120.41M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $187.46M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $186.93M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $183.07M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $188.94M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $159.66M 10-K · filed 2026-03-02 |
| 2024-09-30 | $174.76M 10-Q · filed 2024-10-31 |
| 2023-12-31 | $216.38M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |